Cargando…

A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis

Prurigo nodularis (PN) is a chronic dermatoses characterized by intensely pruritic, excoriated, or lichenified nodules. Standard therapy includes corticosteroids, antihistamines, and phototherapy; however, treatment results are often inadequate or transient. Thalidomide and its analogue lenalidomide...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Victoria M., Maranda, Eric L., Patel, Vivek, Simmons, Brian J., Jimenez, Joaquin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972728/
https://www.ncbi.nlm.nih.gov/pubmed/27289372
http://dx.doi.org/10.1007/s13555-016-0122-9
_version_ 1782446281738682368
author Lim, Victoria M.
Maranda, Eric L.
Patel, Vivek
Simmons, Brian J.
Jimenez, Joaquin J.
author_facet Lim, Victoria M.
Maranda, Eric L.
Patel, Vivek
Simmons, Brian J.
Jimenez, Joaquin J.
author_sort Lim, Victoria M.
collection PubMed
description Prurigo nodularis (PN) is a chronic dermatoses characterized by intensely pruritic, excoriated, or lichenified nodules. Standard therapy includes corticosteroids, antihistamines, and phototherapy; however, treatment results are often inadequate or transient. Thalidomide and its analogue lenalidomide are immunomodulatory drugs that have successfully been used to treat refractory cases of PN. A systematic review was performed evaluating the use of thalidomide and lenalidomide for PN. Eighteen articles were included in this study in which a total of 106 patients were evaluated, of whom 76 (71.7%) had moderate to significant improvement of PN with the use of thalidomide, lenalidomide, or both. Patients given thalidomide were treated with doses of 50–300 mg daily for 1–142 months, with the majority being treated for less than 1 year. Patients treated with lenalidomide were given a daily dose of 5–10 mg from 3 to 24 months. The most common side effects observed were sedation, gastrointestinal symptoms, and transient peripheral neuropathy. While thalidomide and lenalidomide are drugs that have shown promising results in these studies, caution should be taken in prescribing these medications and patients should be informed about the potential side effects. As such, large-scale randomized controlled trials with long-term follow-up are needed to determine appropriate dosing, efficacy, and toxicity profiles.
format Online
Article
Text
id pubmed-4972728
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-49727282016-08-17 A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis Lim, Victoria M. Maranda, Eric L. Patel, Vivek Simmons, Brian J. Jimenez, Joaquin J. Dermatol Ther (Heidelb) Review Prurigo nodularis (PN) is a chronic dermatoses characterized by intensely pruritic, excoriated, or lichenified nodules. Standard therapy includes corticosteroids, antihistamines, and phototherapy; however, treatment results are often inadequate or transient. Thalidomide and its analogue lenalidomide are immunomodulatory drugs that have successfully been used to treat refractory cases of PN. A systematic review was performed evaluating the use of thalidomide and lenalidomide for PN. Eighteen articles were included in this study in which a total of 106 patients were evaluated, of whom 76 (71.7%) had moderate to significant improvement of PN with the use of thalidomide, lenalidomide, or both. Patients given thalidomide were treated with doses of 50–300 mg daily for 1–142 months, with the majority being treated for less than 1 year. Patients treated with lenalidomide were given a daily dose of 5–10 mg from 3 to 24 months. The most common side effects observed were sedation, gastrointestinal symptoms, and transient peripheral neuropathy. While thalidomide and lenalidomide are drugs that have shown promising results in these studies, caution should be taken in prescribing these medications and patients should be informed about the potential side effects. As such, large-scale randomized controlled trials with long-term follow-up are needed to determine appropriate dosing, efficacy, and toxicity profiles. Springer Healthcare 2016-06-11 /pmc/articles/PMC4972728/ /pubmed/27289372 http://dx.doi.org/10.1007/s13555-016-0122-9 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Lim, Victoria M.
Maranda, Eric L.
Patel, Vivek
Simmons, Brian J.
Jimenez, Joaquin J.
A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis
title A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis
title_full A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis
title_fullStr A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis
title_full_unstemmed A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis
title_short A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis
title_sort review of the efficacy of thalidomide and lenalidomide in the treatment of refractory prurigo nodularis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972728/
https://www.ncbi.nlm.nih.gov/pubmed/27289372
http://dx.doi.org/10.1007/s13555-016-0122-9
work_keys_str_mv AT limvictoriam areviewoftheefficacyofthalidomideandlenalidomideinthetreatmentofrefractoryprurigonodularis
AT marandaericl areviewoftheefficacyofthalidomideandlenalidomideinthetreatmentofrefractoryprurigonodularis
AT patelvivek areviewoftheefficacyofthalidomideandlenalidomideinthetreatmentofrefractoryprurigonodularis
AT simmonsbrianj areviewoftheefficacyofthalidomideandlenalidomideinthetreatmentofrefractoryprurigonodularis
AT jimenezjoaquinj areviewoftheefficacyofthalidomideandlenalidomideinthetreatmentofrefractoryprurigonodularis
AT limvictoriam reviewoftheefficacyofthalidomideandlenalidomideinthetreatmentofrefractoryprurigonodularis
AT marandaericl reviewoftheefficacyofthalidomideandlenalidomideinthetreatmentofrefractoryprurigonodularis
AT patelvivek reviewoftheefficacyofthalidomideandlenalidomideinthetreatmentofrefractoryprurigonodularis
AT simmonsbrianj reviewoftheefficacyofthalidomideandlenalidomideinthetreatmentofrefractoryprurigonodularis
AT jimenezjoaquinj reviewoftheefficacyofthalidomideandlenalidomideinthetreatmentofrefractoryprurigonodularis